<i>TP53</i> Gene Therapy as a Potential Treatment for Patients with COVID-19
SGT-53 is a novel investigational agent that comprises an immunoliposome carrying a plasmid vector driving expression of the human <i>TP53</i> gene that encodes wild-type human p53. SGT-53 is currently in phase II human trials for advanced pancreatic cancer. Although p53 is best known as...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/4/739 |
| _version_ | 1797409034604642304 |
|---|---|
| author | Joe B. Harford Sang Soo Kim Kathleen F. Pirollo Esther H. Chang |
| author_facet | Joe B. Harford Sang Soo Kim Kathleen F. Pirollo Esther H. Chang |
| author_sort | Joe B. Harford |
| collection | DOAJ |
| description | SGT-53 is a novel investigational agent that comprises an immunoliposome carrying a plasmid vector driving expression of the human <i>TP53</i> gene that encodes wild-type human p53. SGT-53 is currently in phase II human trials for advanced pancreatic cancer. Although p53 is best known as a tumor suppressor, its participation in both innate and adaptive immune responses is well documented. It is now clear that p53 is an important component of the host response to various viral infections. To facilitate their viral life cycles, viruses have developed a diverse repertoire of strategies for counteracting the antiviral activities of host immune system by manipulating p53-dependent pathways in host cells. Coronaviruses reduce endogenous p53 levels in the cells they infect by enhancing the degradation of p53 in proteasomes. Thus, interference with p53 function is an important component in viral pathogenesis. Transfection of cells by SGT-53 has been shown to transiently produce exogenous p53 that is active as a pleiotropic transcription factor. We herein summarize the rationale for repurposing SGT-53 as a therapy for infection by SARS-CoV-2, the pathogen responsible for the COVID-19 pandemic. Because p53 regulation was found to play a crucial role in different infection stages of a wide variety of viruses, it is rational to believe that restoring p53 function based on SGT-53 treatment may lead to beneficial therapeutic outcomes for infectious disease at large including heretofore unknown viral pathogens that may emerge in the future. |
| first_indexed | 2024-03-09T04:08:27Z |
| format | Article |
| id | doaj.art-26b801d1165c4d7d9935b5d4b34184e7 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T04:08:27Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-26b801d1165c4d7d9935b5d4b34184e72023-12-03T14:03:20ZengMDPI AGViruses1999-49152022-03-0114473910.3390/v14040739<i>TP53</i> Gene Therapy as a Potential Treatment for Patients with COVID-19Joe B. Harford0Sang Soo Kim1Kathleen F. Pirollo2Esther H. Chang3SynerGene Therapeutics, Inc., Potomac, MD 20854, USASynerGene Therapeutics, Inc., Potomac, MD 20854, USADepartment of Oncology, Georgetown University Medical Center, Washington, DC 20007, USADepartment of Oncology, Georgetown University Medical Center, Washington, DC 20007, USASGT-53 is a novel investigational agent that comprises an immunoliposome carrying a plasmid vector driving expression of the human <i>TP53</i> gene that encodes wild-type human p53. SGT-53 is currently in phase II human trials for advanced pancreatic cancer. Although p53 is best known as a tumor suppressor, its participation in both innate and adaptive immune responses is well documented. It is now clear that p53 is an important component of the host response to various viral infections. To facilitate their viral life cycles, viruses have developed a diverse repertoire of strategies for counteracting the antiviral activities of host immune system by manipulating p53-dependent pathways in host cells. Coronaviruses reduce endogenous p53 levels in the cells they infect by enhancing the degradation of p53 in proteasomes. Thus, interference with p53 function is an important component in viral pathogenesis. Transfection of cells by SGT-53 has been shown to transiently produce exogenous p53 that is active as a pleiotropic transcription factor. We herein summarize the rationale for repurposing SGT-53 as a therapy for infection by SARS-CoV-2, the pathogen responsible for the COVID-19 pandemic. Because p53 regulation was found to play a crucial role in different infection stages of a wide variety of viruses, it is rational to believe that restoring p53 function based on SGT-53 treatment may lead to beneficial therapeutic outcomes for infectious disease at large including heretofore unknown viral pathogens that may emerge in the future.https://www.mdpi.com/1999-4915/14/4/739SARS-CoV-2COVID-19p53TP53gene therapyinnate immunity |
| spellingShingle | Joe B. Harford Sang Soo Kim Kathleen F. Pirollo Esther H. Chang <i>TP53</i> Gene Therapy as a Potential Treatment for Patients with COVID-19 Viruses SARS-CoV-2 COVID-19 p53 TP53 gene therapy innate immunity |
| title | <i>TP53</i> Gene Therapy as a Potential Treatment for Patients with COVID-19 |
| title_full | <i>TP53</i> Gene Therapy as a Potential Treatment for Patients with COVID-19 |
| title_fullStr | <i>TP53</i> Gene Therapy as a Potential Treatment for Patients with COVID-19 |
| title_full_unstemmed | <i>TP53</i> Gene Therapy as a Potential Treatment for Patients with COVID-19 |
| title_short | <i>TP53</i> Gene Therapy as a Potential Treatment for Patients with COVID-19 |
| title_sort | i tp53 i gene therapy as a potential treatment for patients with covid 19 |
| topic | SARS-CoV-2 COVID-19 p53 TP53 gene therapy innate immunity |
| url | https://www.mdpi.com/1999-4915/14/4/739 |
| work_keys_str_mv | AT joebharford itp53igenetherapyasapotentialtreatmentforpatientswithcovid19 AT sangsookim itp53igenetherapyasapotentialtreatmentforpatientswithcovid19 AT kathleenfpirollo itp53igenetherapyasapotentialtreatmentforpatientswithcovid19 AT estherhchang itp53igenetherapyasapotentialtreatmentforpatientswithcovid19 |